QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 precigen-reports-responses-to-papzimeos-in-adults-with-recurrent-respiratory-papillomatosis-reinforcing-fda-approval

Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to ...

 precigen-entered-into-a-credit-facility-agreement-with-pharmakon-advisors-for-up-125m-in-non-dilutive-funding

The credit facility provides Precigen with up to $125 million committed across two tranches, subject to the terms and condition...

 jmp-securities-maintains-market-outperform-on-precigen-raises-price-target-to-8

JMP Securities analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target...

 hc-wainwright--co-reiterates-buy-on-precigen-maintains-85-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $8.5 price...

 why-is-precigen-stock-surging-on-friday

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable...

 jp-morgan-upgrades-precigen-to-neutral

JP Morgan analyst Brian Cheng upgrades Precigen (NASDAQ:PGEN) from Underweight to Neutral.

 hc-wainwright--co-maintains-buy-on-precigen-raises-price-target-to-85

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price targ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION